These were some of the biggest movers and shakers in Friday’s trade: Stock gainers
FedEx Corp The stock FDX, +8.47% jumped 7.9% in midday trading, enough to make it the S&P 500 index’s SPX, -1.05% biggest gainer, beating analysts’ estimates in its fiscal third-quarter earnings. The shipping firm also lifted its profit forecast for the full fiscal year, raising its earnings per share to $14.40 from $13.80. American Depositary Receipts (ADRs) of China. Baidu Inc.
BIDU, +5.65% rose 4.1% after winning a permit to provide fully driverless robotaxis services in Beijing. On Thursday, analysts described the selloff as an “overreaction” to its response to ChatGPT. of US-listed shares XPeng Inc. XPEV rose 8.0%, reversing a premarket loss of 4.2%, after the China-based EV maker reported a wider-than-expected loss in the fourth-quarter, revenue that missed expectations and provided a downbeat outlook for the first-quarter, but reassured investors. was that sales growth and market share gains would resume.
Enzo Biochem Inc. Shares ENZ surged 74% premarket after the company announced late on Thursday that it would sell its clinical laboratory unit to LabCorp.
Histogen Inc Stock HSTO, +61.03% surged 72% after the biotech company announced it had been issued a new U.S. patent covering its portfolio of anti-inflammatory caspase inhibitors, including CTS-2090.
First Republic BankNo stock FRC, -26.23% fell 25% to a 12-year low and was by far the S&P 500’s biggest decliner. The stock closed up 9% on Thursday after a consortium of major banks including Bank of America Corp.
And JPMorgan Chase & Co.
And others agreed to make uninsured deposits totaling $30 billion to shore up the struggling bank. In other regional banks, shares of PacWest Bancorp
13% and no drowned Western Alliance Bancorp decreased by 17%.
Credit Suisse Group AG ADRs CS, -5.09% fell more than 7% after the Swiss lender sought a $54 billion lifeline from the Swiss central bank to end a rough week. ADRs fell by around 25% last week.
Diebold Nixdorf Inc.’s stock DBD, -52.39% tumbled 48% to fuel a New York Stock Exchange (NYSE) decline, offering digitizing services to retailers and banks to lenders, which the company said it faces in the near term. Liquidity needed and that “going-concern” apology, disappointed investors.
Sarepta Therapeutics Inc Stock SRPT, -19.69% sank 19% on Thursday after a selloff triggered by an unexpected Food and Drug Administration advisory committee meeting for Sarepta’s investigational gene therapy to treat Duchenne muscular dystrophy.